UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | R | S | T | V | W | Y | Z
Number of items: 139.

A

Abdallah, QMA; Phillips, RM; Johansson, F; Helleday, T; Cosentino, L; Abdel-Rahman, H; Etzad, J; ... Pors, K; + view all (2012) Minor structural modifications to alchemix influence mechanism of action and pharmacological activity. BIOCHEMICAL PHARMACOLOGY , 83 (11) pp. 1514-1522. 10.1016/j.bcp.2012.02.017.

Adair, JR; Howard, PW; Hartley, JA; Williams, DG; Chester, KA; (2012) Antibody-drug conjugates - a perfect synergy. EXPERT OPINION ON BIOLOGICAL THERAPY , 12 (9) pp. 1191-1206. 10.1517/14712598.2012.693473.

Agbamu, DA; Day, N; Walsh, CJ; Hendrickse, CW; Langman, G; Pallan, A; Lowe, A; ... Lees, N; + view all (2012) Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial. The Lancet Oncology , 13 (11) 1152 - 1160. 10.1016/S1470-2045(12)70348-0. Green open access
file

Aksoy, E; Taboubi, S; Torres, D; Delbauve, S; Hachani, A; Whitehead, MA; Pearce, WP; ... Vanhaesebroeck, B; + view all (2012) The p110δ isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat Immunol , 13 (11) pp. 1045-1054. 10.1038/ni.2426.

Alcolea, MP; Casado, P; Rodríguez-Prados, J-C; Vanhaesebroeck, B; Cutillas, PR; (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics , 11 (8) pp. 453-466. 10.1074/mcp.M112.017483.

Anthoney, DA; Naik, J; MacPherson, IRJ; Crawford, D; Hartley, JM; Hartley, JA; Saito, T; ... Evans, TRJ; + view all (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer , 12 , Article 536. 10.1186/1471-2407-12-536. Green open access
file

Arkenau, H-T; Plummer, R; Molife, LR; Olmos, D; Yap, TA; Squires, M; Lewis, S; ... Judson, I; + view all (2012) A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol , 23 (5) pp. 1307-1313. 10.1093/annonc/mdr451.

Arkenau, H-T; Saggese, M; Lemech, C; (2012) Advanced gastric cancer: Is there enough evidence to call second-line therapy standard? WORLD JOURNAL OF GASTROENTEROLOGY , 18 (44) pp. 6376-6378. 10.3748/wjg.v18.i44.6376. Gold open access

Arkenau, H-T; Saggese, M; Lemech, C; (2012) DABRAFENIB MESYLATE Serine/Threonine-Protein Kinase B-raf Inhibitor, Oncolytic. DRUGS OF THE FUTURE , 37 (7) pp. 469-474. 10.1358/dof.2012.37.7.1820872.

Asghar, U; Meyer, T; (2012) Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? JOURNAL OF HEPATOLOGY , 56 (3) pp. 686-695.

B

Bachner, M; Loriot, Y; Gross-Goupil, M; Zucali, PA; Horwich, A; Germa-Lluch, J-R; Kollmannsberger, C; ... De Santis, M; + view all (2012) 2-(18)fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. ANNALS OF ONCOLOGY , 23 (1) pp. 59-64. 10.1093/annonc/mdr052.

Bagnobianchi, A; Spanswick, VJ; Bingham, JP; Kiakos, K; Suarez-Henriques, P; Smith, D; Yong, K; ... Hartley, JA; + view all (2012) Persistence of drug-induced DNA interstrand cross-links distinguishes bendamustine from conventional DNA cross-linking agents. CANCER RESEARCH , 72 10.1158/1538-7445.AM2012-1766.

Banerji, U; van Doorn, L; Papadatos-Pastos, D; Kristeleit, R; Debnam, P; Tall, M; Stewart, A; ... Eskens, FA; + view all (2012) A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res , 18 (9) pp. 2687-2694. 10.1158/1078-0432.CCR-11-3165.

Baud, MGJ; Leiser, T; Haus, P; Samlal, S; Wong, AC; Wood, RJ; Petrucci, V; ... Fuchter, MJ; + view all (2012) Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. J Med Chem , 55 (4) pp. 1731-1750. 10.1021/jm2016182.

Berenjeno, IM; Guillermet-Guibert, J; Pearce, W; Gray, A; Fleming, S; Vanhaesebroeck, B; (2012) Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J , 442 (1) pp. 151-159. 10.1042/BJ20111741.

Butt, MA; Pye, H; Haidry, RJ; Oukrif, D; Rashid, M; Banks, MR; Deonarain, MP; ... Lovat, LB; + view all (2012) ABERRANTLY GLYCOSYLATED MUC1 AS A POTENTIAL THERAPEUTIC TARGET FOR BARRETT'S WITH HIGH GRADE DYSPLASIA AND PRIMARY AND METASTATIC OESOPHAGEAL ADENOCARCINOMA. In: (pp. A301-A301). B M J PUBLISHING GROUP

C

Cain, RJ; Vanhaesebroeck, B; Ridley, AJ; (2012) Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration. Int J Biochem Cell Biol , 44 (11) pp. 1929-1936. 10.1016/j.biocel.2012.07.009.

Cameron, D; Barrett-Lee, P; Canney, P; Banerji, J; Bartlett, J; Bloomfield, D; Bowden, S; ... Bliss, JM; + view all (2012) Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). In: (pp. S3-3-S3-3).

Campbell, NH; Abd Karim, NH; Parkinson, GN; Gunaratnam, M; Petrucci, V; Todd, AK; Vilar, R; (2012) Molecular Basis of Structure-Activity Relationships between Salphen Metal Complexes and Human Telomeric DNA Quadruplexes. JOURNAL OF MEDICINAL CHEMISTRY , 55 (1) pp. 209-222. 10.1021/jm201140v.

Cervantes, A; Markman, B; Siena, S; Pericay, C; Aprile, G; Bridgewater, J; Cubillo, A; ... Tabernero, J; + view all (2012) Translational research with RG7160 (GA201) leads to a phase II clinical study in combination with FOLFIRI in 2nd line metastatic colorectal cancer (mCRC). CANCER RESEARCH , 72 10.1158/1538-7445.AM2012-LB-220.

Chapman, MH; Tidswell, R; Dooley, JS; Sandanayake, NS; Cerec, V; Deheragoda, M; Lee, AJX; ... Pereira, SP; + view all (2012) Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. JOURNAL OF HEPATOLOGY , 56 (4) pp. 877-885.

Chen, C; Constantinou, A; Chester, KA; Vyas, B; Canis, K; Haslam, SM; Dell, A; ... Deonarain, MP; + view all (2012) Glycoengineering Approach to Half-Life Extension of Recombinant Biotherapeutics. BIOCONJUGATE CHEMISTRY , 23 (8) pp. 1524-1533. 10.1021/bc200624a.

Chen, P; Tu, X; Akdemir, F; Chew, SK; Rothenfluh, A; Abrams, JM; (2012) Effectors of alcohol-induced cell killing in Drosophila. Cell Death Differ , 19 (10) pp. 1655-1663. 10.1038/cdd.2012.47.

Corrie, P; Caplin, M; Reed, N; Qain, W; Lao-Sirieix, S-H; Hardy, R; Armstrong, G; ... Meyer, T; + view all (2012) Treatment of advanced neuroendocrine tumors: Results of the UKINETS and NCRI randomized phase II NET01 trial. In: (Proceedings) ASCO Annual Meeting. (pp. 4121-).

Corrie, P; Caplin, M; Reed, N; Qian, W; Lao-Sirieix, S-H; Hardy, R; Armstrong, G; ... Meyer, T; + view all (2012) Treatment of advanced neuroendocrine tumors: Results of the UKINETS and NCRI randomized phase II NET01 trial. In: (Proceedings) 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). AMER SOC CLINICAL ONCOLOGY

D

Dubois, E; Jacoby, M; Blockmans, M; Pernot, E; Schiffmann, SN; Foukas, LC; Henquin, J-C; ... Schurmans, S; + view all (2012) Developmental defects and rescue from glucose intolerance of a catalytically-inactive novel Ship2 mutant mouse. CELLULAR SIGNALLING , 24 (11) pp. 1971-1980. 10.1016/j.cellsig.2012.06.012.

Dunlop, MG; Dobbins, SE; Farrington, SM; Jones, AM; Palles, C; Whiffin, N; Tenesa, A; ... Houlston, RS; + view all (2012) Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet , 44 (7) pp. 770-776. 10.1038/ng.2293.

E

Enting, D; Ang, JE; O'Hanlon-Brown, C; Kristeleit, RS; Uttenreuther-Fischer, M; Pemberton, K; Pelling, K; ... Spicer, J; + view all (2012) A PHASE I STUDY OF DAILY AFATINIB, AN IRREVERSIBLE ERBB FAMILY BLOCKER, COMBINED WITH WEEKLY PACLITAXEL AND 2-WEEKLY BEVACIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMOURS. Annals of Oncology , 23 (Suppl 9) 10.1093/annonc/mds395.

F

Faelber, K; Held, M; Gao, S; Posor, Y; Haucke, V; Noé, F; Daumke, O; (2012) Structural insights into dynamin-mediated membrane fission. Structure , 20 (10) pp. 1621-1628. 10.1016/j.str.2012.08.028.

Falchook, GS; Long, GV; Kurzrock, R; Kim, KB; Arkenau, TH; Brown, MP; Hamid, O; ... Kefford, RF; + view all (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet , 379 (9829) pp. 1893-1901. 10.1016/S0140-6736(12)60398-5.

Feng, H; Hu, B; Jarzynka, MJ; Li, Y; Keezer, S; Johns, TG; Tang, CK; ... Cheng, S-Y; + view all (2012) Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proc Natl Acad Sci U S A , 109 (8) pp. 3018-3023. 10.1073/pnas.1121457109.

Fennell, DA; Swanton, C; (2012) Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer. EPMA J , 3 (1) 6-. 10.1186/1878-5085-3-6.

Fenton, TR; Nathanson, D; Ponte de Albuquerque, C; Kuga, D; Iwanami, A; Dang, J; Yang, H; ... Furnari, FB; + view all (2012) Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. PNAS USA , 109 (35) 14164 - 14169. 10.1073/pnas.1211962109. Green open access
file

Fernandez, AF; Assenov, Y; Ignacio Martin-Subero, J; Balint, B; Siebert, R; Taniguchi, H; Yamamoto, H; ... Esteller, M; + view all (2012) A DNA methylation fingerprint of 1628 human samples. GENOME RESEARCH , 22 (2) pp. 407-419. 10.1101/gr.119867.110.

Fisher, R; Larkin, J; Swanton, C; (2012) Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol , 2 49-. 10.3389/fonc.2012.00049.

Fizazi, K; Scher, HI; Molina, A; Logothetis, CJ; Chi, KN; Jones, RJ; Staffurth, JN; ... de Bono, JS; + view all (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. LANCET ONCOLOGY , 13 (10) pp. 983-992. 10.1016/S1470-2045(12)70379-0.

Flaherty, K; Metric Study Group, ; (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. New England Journal of Medicine 10.1056/NEJMoa1203421.

Forster, M; Mendes, R; Fedele, S; (2012) Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer. CURRENT PHARMACEUTICAL DESIGN , 18 (34) pp. 5431-5441.

Forster, M; Sultan, A; Jerjes, W; Simeon, C; Morley, S; Carnell, D; Hopper, C; (2012) FIRST-IN-MAN PHASE I STUDY OF TPCS2A-BASED PHOTOCHEMICAL INTERNALISATION (PCI) OF BLEOMYCIN IN LOCALLY RECURRENT OR ADVANCED/METASTATIC, CUTANEOUS OR SUBCUTANEOUS MALIGNANCIES. In: (Proceedings) 37th Congress of the European-Society-for-Medical-Oncology (ESMO). (pp. p. 347). OXFORD UNIV PRESS

Forster, MD; Mendes, R; Fedele, S; (2012) Synthetic lethality and PARP-inhibitors in oral and head & neck cancer. Current Pharmaceutical Design

G

Garelnabi, EAE; Pletsas, D; Li, L; Kiakos, K; Karodia, N; Hartley, JA; Phillips, RM; (2012) Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR. ACS MEDICINAL CHEMISTRY LETTERS , 3 (12) pp. 965-968. 10.1021/ml300132t.

Gerlinger, M; Rowan, AJ; Horswell, S; Larkin, J; Endesfelder, D; Gronroos, E; Martinez, P; ... Swanton, C; + view all (2012) Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. NEW ENGLAND JOURNAL OF MEDICINE , 366 (10) pp. 883-892.

Gerlinger, M; Santos, CR; Spencer-Dene, B; Martinez, P; Endesfelder, D; Burrell, RA; Vetter, M; ... Swanton, C; + view all (2012) Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. JOURNAL OF PATHOLOGY , 227 (2) pp. 146-156. 10.1002/path.4006.

Gibson, F; Fern, L; Whelan, J; Pearce, S; Lewis, IJ; Hobin, D; Taylor, RM; (2012) A scoping exercise of favourable characteristics of professionals working in teenage and young adult cancer care: 'thinking outside of the box'. EUROPEAN JOURNAL OF CANCER CARE , 21 (3) pp. 330-339. 10.1111/j.1365-2354.2011.01322.x.

Gibson, F; Shipway, L; Barry, A; Taylor, RM; (2012) What's It Like When You Find Eating Difficult Children's and Parents' Experiences of Food Intake. CANCER NURSING , 35 (4) pp. 265-277. 10.1097/NCC.0b013e31822cbd40.

González-Beltrán, AN; Yong, MY; Dancey, G; Begent, R; (2012) Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy. BMC Res Notes , 5 10-. 10.1186/1756-0500-5-10. Gold open access

Goodwin, R; Giaccone, G; Calvert, H; Lobbezoo, M; Eisenhauer, EA; (2012) Targeted agents: How to select the winners in preclinical and early clinical studies? EUROPEAN JOURNAL OF CANCER , 48 (2) pp. 170-178. 10.1016/j.ejca.2011.09.024.

Greco, FA; Oien, K; Erlander, M; Osborne, R; Varadhachary, G; Bridgewater, J; Cohen, D; (2012) Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. ANNALS OF ONCOLOGY , 23 (2) pp. 298-304. 10.1093/annonc/mdr306.

H

Hall, PS; McCabe, C; Stein, RC; Cameron, D; (2012) Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node-Positive Breast Cancer. Journal of the National Cancer Institute , 104 (1) pp. 56-66. 10.1093/jnci/djr484.

Hartley, JA; Hamaguchi, A; Suggitt, M; Gregson, SJ; Thurston, DE; Howard, PW; (2012) DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057. INVESTIGATIONAL NEW DRUGS , 30 (3) pp. 950-958. 10.1007/s10637-011-9647-z.

Hartley, JA; Hochhauser, D; (2012) Small molecule drugs - optimizing DNA damaging agent-based therapeutics. CURRENT OPINION IN PHARMACOLOGY , 12 (4) pp. 398-402. 10.1016/j.coph.2012.03.008.

Ho, K-K; McGuire, VA; Koo, C-Y; Muir, KW; de Olano, N; Maifoshie, E; Kelly, DJ; ... Lam, EW-F; + view all (2012) Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. J Biol Chem , 287 (2) pp. 1545-1555. 10.1074/jbc.M111.284224.

Howie, AJ; (2012) Diagnosis of amyloid using Congo red. In: Picken, MM and Dogan, A and Herrera, G, (eds.) Amyloid and related disorders: surgical pathology and clinical correlations. (pp. 167-174). Springer: New York, USA.

Howie, AJ; Owen-Casey, MP; (2012) 'Apple-green birefringence' of amyloid stained by Congo red. KIDNEY INTERNATIONAL , 82 (1) p. 114. 10.1038/ki.2012.89.

I

Iorns, E; Ward, TM; Dean, S; Jegg, A; Thomas, D; Murugaesu, N; Sims, D; ... Lippman, M; + view all (2012) Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. BREAST CANCER RESEARCH AND TREATMENT , 135 (1) pp. 79-91. 10.1007/s10549-012-2068-7.

Ip, L; Cia-Viciano, F; Spanswick, V; Pouigiannis, G; Cantley, L; Hartley, J; Hochhauser, D; (2012) Loss of the tumour suppressor inositol polyphosphate 4-phosphatase type II in ovarian cancer-implications for therapy. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE , 30 S19-S19.

Irshad, S; Grigoriadis, A; Lawler, K; Ng, T; Tutt, A; (2012) Profiling the immune stromal interface in breast cancer and its potential for clinical impact. Breast Care (Basel) , 7 (4) pp. 273-280. 10.1159/000341529.

J

Jamal-Hanjani, M; Spicer, J; (2012) Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res , 18 (4) pp. 938-944. 10.1158/1078-0432.CCR-11-2529.

Jaureguiberry, G; De la Dure-Molla, M; Parry, D; Quentric, M; Himmerkus, N; Koike, T; Poulter, J; ... Kleta, R; + view all (2012) Nephrocalcinosis (enamel renal syndrome) caused by autosomal recessive FAM20A mutations. Nephron Physiology , 122 (1-2) 1 - 6. 10.1159/000349989. Green open access
file

Jayakody, SA; (2012) Investigating genetic factors underlying hypopituitarism and septo-optic dysplasia in humans. Doctoral thesis, UCL (University College London).

Jitlal, M; Khan, I; Lee, SM; Hackshaw, A; (2012) Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies. British Journal of Cancer , 107 (6) 910 - 917. 10.1038/bjc.2012.344. Green open access
file

Johnson, RJ; Davies, A; Lee, S-M; Gilson, D; Smith, P; Qian, W; Braganca, N; ... Johnson, P; + view all (2012) A Phase 1 Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients with Primary Central Nervous System Lymphoma (PCNSL). (CRUK/08/010). In: (Proceedings) 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). AMER SOC HEMATOLOGY

K

Karpathakis, A; Caplin, M; Thirlwell, C; (2012) Hitting the target: where do molecularly targeted therapies fit in the treatment scheduling of neuroendocrine tumours? ENDOCRINE-RELATED CANCER , 19 (3) R73-R92. 10.1530/ERC-12-0050.

Khan, MS; Tsigani, T; Garcia-Hernandez, J; Hartley, JA; Caplin, ME; Meyer, T; (2012) Circulating tumor cells as prognostic and predictive markers in neuroendocrine tumors. In: (Proceedings) 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). AMER SOC CLINICAL ONCOLOGY

Klionsky, DJ; Abdalla, FC; Abeliovich, H; Abraham, RT; Acevedo-Arozena, A; Adeli, K; Agholme, L; ... Zuckerbraun, B; + view all (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. AUTOPHAGY , 8 (4) pp. 445-544. 10.4161/auto.19496.

L

Larkin, J; Goh, XY; Vetter, M; Pickering, L; Swanton, C; (2012) Epigenetic regulation in RCC: opportunities for therapeutic intervention? Nat Rev Urol , 9 (3) pp. 147-155. 10.1038/nrurol.2011.236.

Lee, AJX; Roylance, R; Sander, J; Gorman, P; Endesfelder, D; Kschischo, M; Jones, NP; ... Swanton, C; + view all (2012) CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. JOURNAL OF PATHOLOGY , 226 (3) pp. 482-494. 10.1002/path.2998.

Lee, AJX; Swanton, C; (2012) Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics. BIOCHEMICAL PHARMACOLOGY , 83 (8) pp. 1013-1020. 10.1016/j.bcp.2011.12.008.

Lee, M; Satam, V; Babu, B; Gregory, M; Bowerman, M; Savagian, M; Lee, M; ... Hartley, JA; + view all (2012) Complete analysis on the two base pair sequence recognition by Hx (p-anisylbenzimidazole)center dot pyrrole and Hx center dot imidazole pairings. In: (Proceedings) 244th National Fall Meeting of the American-Chemical-Society (ACS). AMER CHEMICAL SOC

Lee, M; Satam, V; Babu, B; Porte, A; Savagian, M; Lee, MD; Liu, Y; ... Hartley, JA; + view all (2012) Synthesis and DNA binding properties of 1-(3-aminopropyl)imidazole-containing triamide f-Im*PyIm: a novel diamino polyamide designed to target 5 '-ACGCGT-3 '. In: (Proceedings) 244th National Fall Meeting of the American-Chemical-Society (ACS). AMER CHEMICAL SOC

Lee, SM; Khan, I; Upadhyay, S; Lewanski, C; Falk, S; Skailes, G; Marshall, E; ... Boshoff, C; + view all (2012) First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. LANCET ONCOLOGY , 13 (11) pp. 1161-1170. 10.1016/S1470-2045(12)70412-6. Gold open access

Lemech, C; Arkenau, H-T; (2012) Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol , 6 pp. 53-66. 10.4137/CMO.S5855. Gold open access

Lemech, C; Infante, J; Arkenau, H-T; (2012) The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY , 4 (2) pp. 61-73. 10.1177/1758834011432949. Gold open access

Lombardo, CM; Welsh, SJ; Strauss, SJ; Dale, AG; Todd, AK; Nanjunda, R; Wilson, WD; (2012) A novel series of G-quadruplex ligands with selectivity for HIF-expressing osteosarcoma and renal cancer cell lines. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 22 (18) pp. 5984-5988. 10.1016/j.bmcl.2012.07.009.

Lucas, G; Win, N; Calvert, A; Green, A; Griffin, E; Bendukidze, N; Hopkins, M; ... Massey, E; + view all (2012) Reducing the incidence of TRALI in the UK: the results of screening for donor leucocyte antibodies and the development of national guidelines. VOX SANGUINIS , 103 (1) pp. 10-17. 10.1111/j.1423-0410.2011.01570.x.

M

Maharaj, L; Popat, R; Gribben, JG; Joel, S; (2012) IL-6, IL-8 and VEGF Neutralisation Restores Drug Sensitivity to Conventional and Novel Treatment Combinations in a Multiple Myeloma Bone Marrow Micro-Environment Model. In: (Proceedings) 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). AMER SOC HEMATOLOGY

Mankia, SK; Miller, RF; Edwards, SG; Ramsay, A; Lee, SM; (2012) Highly Active Antiretroviral Therapy Alone is an Effective Treatment for Lymphadenopathic Kaposi Sarcoma Demonstrated by a Clinical and F-18 FDG Positron Emission Tomography/Computed Tomography Response. CLINICAL ONCOLOGY , 24 (4) pp. 309-311. 10.1016/j.clon.2012.01.006.

Mankia, SK; Miller, RF; Edwards, SG; Ramsay, A; Lee, SM; (2012) The Response of HIV-Associated Lymphadenopathic Kaposi Sarcoma to Highly Active Antiretroviral Therapy Evaluated by F-18-FDG PET/CT. Clinical Nuclear Medicine , 37 (7) pp. 692-693. 10.1097/RLU.0b013e3182485261.

Marquardt, J; Begent, RHJ; Chester, K; Huston, JS; Bradbury, A; Scott, JK; Thorpe, PE; ... Weiner, LM; + view all (2012) IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA. MAbs , 4 (6) pp. 648-652. 10.4161/mabs.22221.

Maughan, T; Wilson, RH; Williams, GT; Seymour, MT; Richman, SD; Quirke, P; Pope, J; ... Kaplan, RS; + view all (2012) FOCUS 3: A study to determine the feasibility of molecular selection of therapy using K-RAS, B-RAF, and topo-1 in patients with advanced colorectal cancer (ACRC). J Clin Oncol , 30 (4_suppl) 563-.

Maxwell, MJ; Tsantikos, E; Kong, AM; Vanhaesebroeck, B; Tarlinton, DM; Hibbs, ML; (2012) Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease. J Autoimmun , 38 (4) pp. 381-391. 10.1016/j.jaut.2012.04.001.

McGranahan, N; Burrell, RA; Endesfelder, D; Novelli, MR; Swanton, C; (2012) Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO REPORTS , 13 (6) pp. 528-538. 10.1038/embor.2012.61.

McTiernan, A; Jinks, RC; Sydes, MR; Uscinska, B; Hook, JM; van Glabbeke, M; Bramwell, V; ... Whelan, JS; + view all (2012) Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. European Journal of Cancer , 48 (5) 703 - 712. 10.1016/j.ejca.2011.09.012. Green open access
file

Mendoza-Naranjo, A; Wai, DH; Farrar, JE; Zhu, Q; Mistry, P; Lazic, N; Rojas Ayala, FR; ... Sorensen, PH; + view all (2012) ErbB4 is a novel driver of metastasis and anoikis resistance in Ewing's sarcoma. CANCER RESEARCH , 72 10.1158/1538-7445.AM2012-431.

Meyer, R; Kulinskaya, E; Briassoulis, G; Taylor, RM; Cooper, M; Pathan, N; Habibi, P; (2012) The Challenge of Developing a New Predictive Formula to Estimate Energy Requirements in Ventilated Critically Ill Children. NUTRITION IN CLINICAL PRACTICE , 27 (5) pp. 669-676. 10.1177/0884533612448479.

Meyer, T; Asghar, U; (2012) Reply to: "Sorafenib prolongs survival, but what happens to the symptoms?". JOURNAL OF HEPATOLOGY , 57 (1) p. 223.

Meyer, T; Caplin, M; Reed, N; Qian, W; Lao-Sirieix, S; Armstrong, G; Valle, J; ... Corrie, P; + view all (2012) TREATMENT OF ADVANCED NEUROENDOCRINE TUMOURS: FINAL RESULTS OF THE UKINETS AND NCRI RANDOMISED PHASE 2 NET01 TRIAL. In: (Proceedings) 37th Congress of the European-Society-for-Medical-Oncology (ESMO). (pp. pp. 378-379). OXFORD UNIV PRESS

Meyer, T; Fox, R; Bird, D; Watkinson, A; Hacking, N; Stocken, D; Johnson, P; (2012) TACE 2: A randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC). In: (Proceedings) ASCO Annual Meeting. (pp. 4150-).

Meyer, T; Kirkwood, A; Gillmore, R; (2012) Reply to: "Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?". JOURNAL OF HEPATOLOGY , 57 (1) pp. 225-226.

Miller, J; Doss, M; McQuillen, R; Shaller, CC; Tolner, B; Yu, JQ; Chester, K; (2012) Impact of expression system on the function of the C6.5 diabody PET radiotracer. TUMOR BIOLOGY , 33 (3) pp. 617-627. 10.1007/s13277-012-0361-z.

Miller, J; Doss, M; McQuillen, R; Shaller, CC; Tolner, B; Yu, JQ; Chester, K; (2012) Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumor Biology pp. 1-11.

Miranda, E; Maya Pineda, H; Öberg, D; Cherubini, G; Garate, Z; Lemoine, NR; Halldén, G; (2012) Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region. PLoS ONE , 7 (10) , Article e46617. 10.1371/journal.pone.0046617. Green open access
file

N

Nagano, K; Akpan, A; Warnasuriya, G; Corless, S; Totty, N; Yang, A; Stein, R; ... Naaby-Hansen, S; + view all (2012) Functional Proteomic Analysis of Long-term Growth Factor Stimulation and Receptor Tyrosine Kinase Coactivation in Swiss 3T3 Fibroblasts. Molecular & Cellular Proteomics , 11 (12) pp. 1690-1708. 10.1074/mcp.M112.019778. Green open access
file

Natrajan, R; Mackay, A; Lambros, MB; Weigelt, B; Wilkerson, PM; Manie, E; Grigoriadis, A; ... Reis-Filho, JS; + view all (2012) A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. JOURNAL OF PATHOLOGY , 227 (1) pp. 29-41. 10.1002/path.4003.

O

Ortega-Molina, A; Efeyan, A; Lopez-Guadamillas, E; Muñoz-Martin, M; Gómez-López, G; Cañamero, M; Mulero, F; ... Serrano, M; + view all (2012) Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab , 15 (3) pp. 382-394. 10.1016/j.cmet.2012.02.001.

P

Palmer, D; Loembe, AB; Studeny, M; Hocke, J; Meyer, T; (2012) PHASE I STUDY OF NINTEDANIB (BIBF 1120) IN EUROPEAN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA. In: (Proceedings) 37th Congress of the European-Society-for-Medical-Oncology (ESMO). (pp. p. 245). OXFORD UNIV PRESS

Pan, X; Hartley, JM; Hartley, JA; White, KN; Wang, Z; Bligh, SWA; (2012) Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. PHYTOMEDICINE , 19 (7) pp. 618-624. 10.1016/j.phymed.2012.02.003.

Pericleous, M; Lumgair, H; Baneke, A; Morgan-Rowe, L; E Caplin, M; Luong, TV; Thirlwell, C; ... Toumpanakis, C; + view all (2012) Appendiceal goblet cell carcinoid tumour: a case of unexpected lung metastasis. Case Rep Oncol , 5 (2) pp. 332-338. 10.1159/000339607.

Pericleous, M; Lumgair, H; Reiner, J; Marelli, L; Caplin, M; Meyer, T; Toumpanakis, C; (2012) Bronchial neuroendocrine tumors: A retrospective review of management and outcomes in 116 patients. In: (Proceedings) 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). AMER SOC CLINICAL ONCOLOGY

Pericleous, M; Toumpanakis, C; Lumgair, H; Reiner, J; Marelli, L; Meyer, T; Caplin, M; (2012) Diagnostic Features and Management Outcomes in Bronchopulmonary Neuroendocrine Tumors: A Clinical Study of 116 Patients. In: (Proceedings) 9th Annual European-Neuroendocrine-Tumor-Society (ENETS) Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. (pp. p. 54). KARGER

Perisoglou, M; Trani, L; Strauss, S; Hartley, J; Hartley, J; Seddon, B; Thomas, E; (2012) EFFICACY AND SAFETY OF GLUCARPIDASE FOR ROUTINE USE AFTER HIGH DOSE METHOTREXATE IN PATIENTS WITH OSTEOSARCOMA. PEDIATRIC BLOOD & CANCER , 59 (6) p. 1048.

Ploquin, A; Olmos, D; Lacombe, D; A'Hern, R; Duhamel, A; Twelves, C; Marsoni, S; ... Penel, N; + view all (2012) Prediction of early death among patients enrolled in phase i trials: Development and validation of a new model based on platelet count and albumin. British Journal of Cancer , 107 (7) pp. 1025-1030. 10.1038/bjc.2012.371.

Porcelli, L; Quatrale, AE; Mantuano, P; Silvestris, N; Brunetti, AE; Calvert, H; Paradiso, A; (2012) Synthetic Lethality to Overcome Cancer Drug Resistance. CURRENT MEDICINAL CHEMISTRY , 19 (23) pp. 3858-3873.

R

Raja, F; Kaler, M; Amadeo, G; Hadwin, R; Kristeleit, RS; McCormack, M; Mould, T; ... Ledermann, JA; + view all (2012) LATE RELAPSED OVARIAN CANCER. International Journal of Gynecological Cancer , 22 (Suppl 3)

Raja, FA; Hook, JM; Ledermann, JA; (2012) Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. CANCER TREATMENT REVIEWS , 38 (6) pp. 662-672. 10.1016/j.ctrv.2011.11.009.

Ramage, JK; Ahmed, A; Ardill, J; Bax, N; Breen, DJ; Caplin, ME; Corrie, P; ... Grossman, AB; + view all (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). GUT , 61 (1) pp. 6-32. 10.1136/gutjnl-2011-300831.

Richards, FM; Tape, CJ; Jodrell, DI; Murphy, G; (2012) Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One , 7 (7) , Article e40597. 10.1371/journal.pone.0040597.

Rossi, A; Di Maio, M; Chiodini, P; Rudd, RM; Okamoto, H; Skarlos, DV; Frueh, M; ... Lee, S-M; + view all (2012) Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. JOURNAL OF CLINICAL ONCOLOGY , 30 (14) pp. 1692-1698. 10.1200/JCO.2011.40.4905.

S

Satam, V; Babu, B; Chavda, S; Savagian, M; Sjoholm, R; Tzou, S; Liu, Y; ... Lee, M; + view all (2012) Novel diamino imidazole and pyrrole-containing polyamides: Synthesis and DNA binding studies of mono- and diamino-phenyl-ImPy*Im polyamides designed to target 5 '-ACGCGT-3 '. BIOORGANIC & MEDICINAL CHEMISTRY , 20 (2) pp. 693-701. 10.1016/j.bmc.2011.12.010.

Satam, V; Babu, B; Chavda, S; Savagian, M; Sjoholm, R; Tzou, S; Ramos, J; ... Lee, M; + view all (2012) Novel diamino imidazole and pyrrole-containing polyamides: Synthesis and DNA binding studies of mono- and diamino-phenyl-ImPy*Im polyamides designed to target 5 '-ACGCGT-3 ' (vol 20, pg 693, 2012). BIOORGANIC & MEDICINAL CHEMISTRY , 20 (15) p. 4881. 10.1016/j.bmc.2012.06.037.

Satam, V; Babu, B; Porte, A; Savagian, M; Lee, M; Smeltzer, T; Liu, Y; ... Lee, M; + view all (2012) Synthesis and DNA binding properties of 1-(3-aminopropyl)-imidazole-containing triamide f-Im*PyIm: A novel diamino polyamide designed to target 5 '-ACGCGT-3 '. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 22 (18) pp. 5898-5902. 10.1016/j.bmcl.2012.07.071.

Sengerová, B; Allerston, CK; Abu, M; Lee, SY; Hartley, J; Kiakos, K; Schofield, CJ; ... McHugh, PJ; + view all (2012) Characterization of the human SNM1A and SNM1B/Apollo DNA repair exonucleases. Journal of Biological Chemistry , 287 (31) 26254 -26267. 10.1074/jbc.M112.367243. Green open access
file

Slater, S; Witteveen, PO; Plummer, R; Kristeleit, R; Evans, TRJ; Reyderman, L; de las Heras, B; ... Schellens, JHM; + view all (2012) 599 Effect of Food On Relative Bioavailability of E7820 in Cancer Patients. European Journal of Cancer , 48 (S6) p. 184. 10.1016/S0959-8049(12)72396-1.

Spanswick, VJ; Lowe, HL; Newton, C; Bingham, JP; Bagnobianchi, A; Kiakos, K; Craddock, C; ... Hartley, JA; + view all (2012) Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer , 12 , Article 436. 10.1186/1471-2407-12-436. Green open access
file

Staples, CJ; Myers, KN; Beveridge, RDD; Patil, AA; Lee, AJX; Swanton, C; Howell, M; ... Collis, SJ; + view all (2012) The centriolar satellite protein Cep131 is important for genome stability. J Cell Sci , 125 (Pt 20) pp. 4770-4779. 10.1242/jcs.104059.

Swanton, C; (2012) Intratumor Heterogeneity: Evolution through Space and Time. CANCER RESEARCH , 72 (19) pp. 4875-4882. 10.1158/0008-5472.CAN-12-2217.

T

Thirlwell, C; Feber, A; Lechner, M; Teschendorff, AE; Beck, S; (2012) Comments on: Interpretation of genome-wide infinium methylation data from ligated DNA in formalin-fixed paraffin-embedded paired tumor and normal tissue. BMC Res Notes , 5 631-. 10.1186/1756-0500-5-631. Gold open access

Thirlwell, C; Sasmaz, S; Dibra, H; Feber, A; Butcher, L; Meyer, T; Davidson, B; ... Beck, S; + view all (2012) The First Neuroendocrine Tumor Methylome Using Methylation-Specific Immunoprecipitation Followed by Second Generation Sequencing - MeDIP-seq. In: (Proceedings) 9th Annual European-Neuroendocrine-Tumor-Society (ENETS) Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. (pp. p. 14). KARGER

Toumpanakis, C; Baneke, A; Pericleous, M; Meyer, T; Caplin, M; (2012) Goblet Cell Appendiceal Neuroendocrine Tumors: Diagnosis, Recurrence Rates, Treatment and Survival. A Series of 37 Patients. In: (Proceedings) 9th Annual European-Neuroendocrine-Tumor-Society (ENETS) Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. (pp. p. 64). KARGER

Toumpanakis, C; Baneke, A; Pericleous, M; Meyer, T; Caplin, ME; (2012) Diagnostic and therapeutic outcomes in goblet cell appendiceal neuroendocrine tumors. In: (Proceedings) 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). AMER SOC CLINICAL ONCOLOGY

Treins, C; Alliouachene, S; Hassouna, R; Xie, Y; Birnbaum, MJ; Pende, M; (2012) The combined deletion of S6K1 and Akt2 deteriorates glycemic control in a high-fat diet. Mol Cell Biol , 32 (19) pp. 4001-4011. 10.1128/MCB.00514-12.

Tsochatzis, EA; Meyer, T; Burroughs, AK; (2012) Hepatocellular carcinoma. N.Engl.J.Med. , 366 (1) pp. 92-93. 10.1056/NEJMc1112501#SA2.

Tzenaki, N; Andreou, M; Stratigi, K; Vergetaki, A; Makrigiannakis, A; Vanhaesebroeck, B; Papakonstanti, EA; (2012) High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation. FASEB J , 26 (6) pp. 2498-2508. 10.1096/fj.11-198192.

V

Vermeer, LS; Fruhwirth, GO; Pandya, P; Ng, T; Mason, AJ; (2012) NMR metabolomics of MTLn3E breast cancer cells identifies a role for CXCR4 in lipid and choline regulation. J Proteome Res , 11 (5) pp. 2996-3003. 10.1021/pr300111x.

Vincenzi, B; Santini, D; Schiavon, G; Frezza, AM; Dileo, P; Silletta, M; Bertoldo, F; ... Tonini, G; + view all (2012) Bone metastases in soft tissue sarcoma patients: A survey of natural, prognostic value, and treatment. In: (Proceedings) 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). AMER SOC CLINICAL ONCOLOGY

W

Wang, Y; Wang, XD; Lapi, E; Sullivan, A; Jia, W; He, Y-W; Ratnayaka, I; ... Lu, X; + view all (2012) Autophagic activity dictates the cellular response to oncogenic RAS. Proc Natl Acad Sci U S A , 109 (33) pp. 13325-13330. 10.1073/pnas.1120193109.

Wangteeraprasert, R; Lipipun, V; Gunaratnam, M; Neidle, S; Gibbons, S; Likhitwitayawuid, K; (2012) Bioactive Compounds from Carissa spinarum. PHYTOTHERAPY RESEARCH , 26 (10) pp. 1496-1499. 10.1002/ptr.4607.

Weatherstone, K; Meyer, T; (2012) Streptozocin-based chemotherapy is not history in neuroendocrine tumours. Targeted Oncology , 7 (3) pp. 161-168. 10.1007/s11523-012-0224-y.

Weigelt, B; Reis-Filho, JS; Swanton, C; (2012) Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations. ANNALS OF ONCOLOGY , 23 pp. 211-218. 10.1093/annonc/mds323.

Westbury, CB; Yarnold, JR; (2012) Radiation Fibrosis - Current Clinical and Therapeutic Perspectives. CLINICAL ONCOLOGY , 24 (10) pp. 657-672. 10.1016/j.clon.2012.04.001.

Whelan, J; McTiernan, A; Cooper, N; Wong, YK; Francis, M; Vernon, S; Strauss, SJ; (2012) Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer , 131 (4) E508-E517. 10.1002/ijc.26426.

Whelan, JS; Jinks, RC; McTiernan, A; Sydes, MR; Hook, JM; Trani, L; Uscinska, B; ... Gelderblom, H; + view all (2012) Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. ANNALS OF ONCOLOGY , 23 (6) pp. 1607-1616. 10.1093/annonc/mdr491.

Whitehead, MA; Bombardieri, M; Pitzalis, C; Vanhaesebroeck, B; (2012) Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter. Biochem J , 443 (3) pp. 857-867. 10.1042/BJ20112214.

Windsor, RE; Strauss, SJ; Kallis, C; Wood, NE; Whelan, JS; (2012) Germline Genetic Polymorphisms May Influence Chemotherapy Response and Disease Outcome in Osteosarcoma. CANCER , 118 (7) pp. 1856-1867. 10.1002/cncr.26472.

Windsor, RE; Strauss, SJ; Kallis, C; Wood, NE; Whelan, JS; (2012) Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: A pilot study. Cancer , 118 (7) pp. 1856-1867. 10.1002/cncr.26472.

Y

Yap, TA; Gerlinger, M; Futreal, PA; Pusztai, L; Swanton, C; (2012) Intratumor Heterogeneity: Seeing the Wood for the Trees. SCIENCE TRANSLATIONAL MEDICINE , 4 (127) 10.1126/scitranslmed.3003854.

Yap, TA; Swanton, C; de Bono, JS; (2012) Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? EPMA J , 3 (1) 3-. 10.1007/s13167-011-0138-2.

Young, RJ; Tin, AW; Brown, NJ; Jitlal, M; Lee, SM; Woll, PJ; (2012) Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. BRITISH JOURNAL OF CANCER , 106 (6) pp. 1153-1159. 10.1038/bjc.2012.50.

Z

Zwaenepoel, O; Tzenaki, N; Vergetaki, A; Makrigiannakis, A; Vanhaesebroeck, B; Papakonstanti, EA; (2012) Functional CSF-1 receptors are located at the nuclear envelope and activated via the p110δ isoform of PI 3-kinase. FASEB J , 26 (2) pp. 691-706. 10.1096/fj.11-189753.

This list was generated on Sun Oct 15 02:13:43 2017 BST.